Developing Efficient Downstream Purification Processes for Bispecific Antibodies

In this webinar, learn about the latest advancements in purification workflows for bispecific antibodies (BsAbs). Downstream purification faces a major obstacle due to the intricate composition of BsAbs, which frequently results in low yields and increased complexity.

Purification strategies and technologies are being developed to overcome these obstacles, aiming to improve the efficiency and scalability of BsAb purification processes. Modern chromatographic resins can provide researchers with new solutions to optimize their downstream processes and increase the production of BsAbs for a variety of therapeutic applications. These advancements in purification technologies can lead to higher purity levels and increased productivity, ultimately benefiting the biopharmaceutical industry.

This webinar showcases a series of case studies that focus on purification strategies utilizing modern chromatography resins to overcome heterogeneity, impurities, and aggregation in BsAb purification.

Key takeaways:

• Learn how modern chromatographic resins can optimize purification workflows and enhance BsAb production
• Analyze case studies highlighting the effectiveness in overcoming challenges in BsAb purification

About the speaker:

William H. Rushton is a chromatography support scientist for Bio-Rad Laboratories. Prior to joining Bio‑Rad, he worked at Centocor from 1997–2007 in the process development group. He developed the downstream purification processes for Simponi^® and Stelara^®. In 2007, Rushton joined Charles River Laboratories as manager of the process validation group, performing viral clearance studies. In 2009, he moved to Auxilium Pharmaceuticals as a senior scientist in process development. He supported the BLA filing and post marketing activities for Xiaflex^®. Rushton obtained a master’s degree in biomedical sciences from Philadelphia College and a bachelor’s degree from St. Joseph’s University.